Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERT 
Certara Inc (CERT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CERT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.11
1 Year Target Price $14.11
| 4 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.21% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.76B USD | Price to earnings Ratio 217.4 | 1Y Target Price 14.11 |
Price to earnings Ratio 217.4 | 1Y Target Price 14.11 | ||
Volume (30-day avg) 11 | Beta 1.42 | 52 Weeks Range 8.63 - 15.69 | Updated Date 08/29/2025 |
52 Weeks Range 8.63 - 15.69 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.1 | Actual 0.07 |
Profitability
Profit Margin 1.97% | Operating Margin (TTM) 4.97% |
Management Effectiveness
Return on Assets (TTM) 1.31% | Return on Equity (TTM) 0.75% |
Valuation
Trailing PE 217.4 | Forward PE 25.25 | Enterprise Value 1887248314 | Price to Sales(TTM) 4.34 |
Enterprise Value 1887248314 | Price to Sales(TTM) 4.34 | ||
Enterprise Value to Revenue 4.65 | Enterprise Value to EBITDA 18.23 | Shares Outstanding 160624000 | Shares Floating 120226750 |
Shares Outstanding 160624000 | Shares Floating 120226750 | ||
Percent Insiders 2.51 | Percent Institutions 105.57 |
Upturn AI SWOT
Certara Inc
Company Overview
History and Background
Certara, Inc. was founded in 2008 as a result of the merger of Pharsight Corporation, Tripos International, and Newport Biosystems. It provides biosimulation software and services to accelerate drug development.
Core Business Areas
- Software: Development and sale of proprietary biosimulation software platforms used by pharmaceutical companies and regulatory agencies.
- Services: Consulting services, including model-informed drug development (MIDD), regulatory strategy, and clinical trial optimization.
Leadership and Structure
Certara is led by CEO William F. Feehery. The company operates with a functional structure, comprising software development, sales and marketing, consulting services, and administrative functions.
Top Products and Market Share
Key Offerings
- MarketShare (%): 25-35
- Simcyp Simulator: A physiologically-based pharmacokinetic (PBPK) modeling platform used to predict drug absorption, distribution, metabolism, and excretion (ADME). Estimated market share of PBPK modeling software is 25-35%. Competitors include Dassault Systu00e8mes (BIOVIA) and Open Systems Pharmacology.
- MarketShare (%): Data Unavailable
- Phoenix WinNonlin: A pharmacokinetic and pharmacodynamic (PK/PD) modeling software platform used for non-compartmental analysis and statistical modeling. Market share data unavailable but it is a leading PK/PD software. Competitors include NonMEM, R (open-source), and SAS.
- D360: A data analytics and knowledge management platform. Market share data is not readily available. Competitors include Spotfire (TIBCO) and other data analytics packages tailored for Pharma/Bio.
- MarketShare (%): Data Unavailable
Market Dynamics
Industry Overview
The pharmaceutical and biotech industries face increasing pressure to accelerate drug development timelines and reduce costs. Biosimulation is becoming an increasingly important tool to achieve these goals, driven by regulatory acceptance and technological advancements.
Positioning
Certara is a leading provider of biosimulation software and services, positioned to benefit from the growing adoption of model-informed drug development (MIDD) approaches. Its competitive advantage lies in its comprehensive suite of software and services, coupled with deep scientific expertise.
Total Addressable Market (TAM)
The global biosimulation market is projected to reach billions of USD. Certara is positioned to capture a significant portion of this market by providing both software and services, serving the entire spectrum of the drug development process.
Upturn SWOT Analysis
Strengths
- Leading market position in biosimulation
- Comprehensive suite of software and services
- Deep scientific expertise
- Strong relationships with regulatory agencies
- Established reputation with pharmaceutical customers
Weaknesses
- Dependence on pharmaceutical industry spending
- Relatively high price point may limit adoption by smaller companies
- Integration of acquired companies can be challenging
- Potential for disruption from open-source alternatives
Opportunities
- Increasing regulatory acceptance of biosimulation
- Expanding applications of biosimulation in drug development
- Growth in emerging markets
- Strategic acquisitions to expand product portfolio
- Development of cloud-based solutions
Threats
- Competition from other biosimulation software providers
- Economic downturn impacting pharmaceutical R&D spending
- Changes in regulatory requirements
- Data security and privacy concerns
- Development of competing technologies
Competitors and Market Share
Key Competitors
- Dassault Systu00e8mes (BIOVIA)
- Open Systems Pharmacology
- Certara Consulting
Competitive Landscape
Certara holds a competitive advantage in biosimulation software. BIOVIA is an established player in scientific software, Open Systems Pharmacology is Open-Source software. Certara's services offering provides an additional competitive edge.
Major Acquisitions
BaseCase
- Year: 2022
- Acquisition Price (USD millions): 92
- Strategic Rationale: Expands Certara's offering into market access and health economics, providing a comprehensive solution for drug development and commercialization.
Growth Trajectory and Initiatives
Historical Growth: Certara's historical growth has been driven by increasing adoption of biosimulation in drug development and strategic acquisitions.
Future Projections: Future growth is projected to be driven by increasing regulatory acceptance of biosimulation, expansion into new markets, and continued innovation in its software and services.
Recent Initiatives: Recent strategic initiatives include acquisitions to expand product portfolio and the development of cloud-based solutions.
Summary
Certara is a well-positioned company in the growing biosimulation market, bolstered by regulatory acceptance and strategic acquisitions. Its comprehensive suite of software and services provides a competitive edge. However, reliance on pharmaceutical industry spending and competition remain key risks. Expansion into new markets and continued innovation are critical for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may vary. Future performance is subject to various risks and uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Certara Inc
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2020-12-11 | CEO & Director Dr. William F. Feehery Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1487 | Website https://www.certara.com |
Full time employees 1487 | Website https://www.certara.com | ||
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.